...
首页> 外文期刊>Chinese Journal of Contemporary Neurology and Neurosurgery >Research progress of MRI in glioma grading and molecular genetic biomarkers
【24h】

Research progress of MRI in glioma grading and molecular genetic biomarkers

机译:MRI在神经胶质瘤分级和分子遗传标志物中的研究进展

获取原文
           

摘要

The pathological and imaging diagnosis of glioma has significantly evolved in recent years. Glioma grading, together with a number of molecular genetic biomarkers, has been recognized as an important prognostic and predictive factor, which can also guide the treatment strategy of glioma. This article highlights the research progress of MRI for noninvasively grading and molecular characterization of gliomas, including diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), diffusion kurtosis imaging (DKI), dynamic contrast-enhanced MRI (DCE-MRI), perfusion-weighted imaging (PWI) and magnetic resonance spectroscopy (MRS). The multiparametric imaging data analysis could improve imaging diagnosis, introduce the potential to noninvasively detect underlying molecular features of glioma, finally improve the accuracy of prognosis prediction and guide the individual-based treatment for glioma patients. DOI: 10.3969/j.issn.1672-6731.2017.01.013
机译:近年来,神经胶质瘤的病理学和影像学诊断已有显着发展。胶质瘤分级以及许多分子遗传生物标志物已被认为是重要的预后和预测因素,也可指导神经胶质瘤的治疗策略。本文着重介绍了MRI在神经胶质瘤非侵入性分级和分子表征方面的研究进展,包括弥散加权成像(DWI),弥散张量成像(DTI),弥散峰度成像(DKI),动态对比增强MRI(DCE-MRI) ,灌注加权成像(PWI)和磁共振波谱(MRS)。多参数影像数据分析可以改善影像学诊断,为无创检测神经胶质瘤的潜在分子特征提供潜力,最终提高预后预测的准确性,并指导针对神经胶质瘤患者的个体化治疗。 DOI:10.3969 / j.issn.1672-6731.2017.01.013

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号